Business Insider: COVID-19 vaccines sparks expansion of RNA research

Business Insider reports on GreenLight Bioscience’s plans to expand its RNA research work, including to include human therapeutics. An extract from the article is below:

For instance, GreenLight Biosciences expanded its mRNA work last year from focusing on pesticide alternatives to include human therapeutics. Now, GreenLight is riding the mRNA hype to a public debut, agreeing to a $1.2 billion special-purpose acquisition company deal in August.

“GreenLight aims to solve some of the world’s biggest problems with RNA, from affordable vaccines and therapies to protecting honeybees,” GreenLight CEO Andrey Zarur said in a statement, adding that clinical trials for its COVID-19 vaccine were scheduled to begin next year.

Read the full article here.

Find out more about how GreenLight manufactures RNA here.